Progesterone action in breast, uterine, and ovarian cancers

Journal of Molecular Endocrinology

Volumn 54, Issue 2, 2015, Pages R31-R53

  Diep, Caroline H ^a   Daniel, Andrea R ^a   Mauro, Laura J ^a   Knutson, Todd P ^a   Lange, Carol A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Cancer; Endometrial; Isoforms; Ovarian cancer; Progesterone; Progesterone receptor; Progestin; Uterine

Indexed keywords

ANTIGESTAGEN; GESTAGEN; PROGESTERONE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ANGIOGENESIS; BREAST CANCER; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; DECIDUALIZATION; DNA METHYLATION; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM CANCER; HETEROZYGOSITY LOSS; HUMAN; LEIOMYOMA; LIGAND BINDING; NONHUMAN; OVARY CANCER; OVARY TUMOR; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION INITIATION; UTERUS CANCER; BIOLOGICAL MODEL; BREAST NEOPLASMS; FEMALE; METABOLISM; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PROGESTERONE; RECEPTORS, PROGESTERONE; UTERINE CERVICAL NEOPLASMS;

EID: 84929120870     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0252     Document Type: Review

References (210)

1. Abdel-Hafiz H, Takimoto GS, Tung L & Horwitz KB 2002 The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. Journal of Biological Chemistry 277 33950-33956. (doi:10.1074/jbc.M204573200)
2. Abdel-Hafiz H, Dudevoir ML & Horwitz KB 2009 Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. Journal of Biological Chemistry 284 9099-9108. (doi:10.1074/jbc.M805226200)
3. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A & Sasano H 2000 Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. British Journal of Cancer 83 1488-1494. (doi:10.1054/bjoc.2000.1463)
4. Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N & Sasano H 2002 Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Japanese Journal of Cancer Research 93 807-815. (doi:10.1111/j.1349-7006.2002.tb01323.x)
5. American Cancer Society 2014 Cancer Facts and Figures. Atlanta GA: American Cancer Society.
6. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE & Lindeman GJ 2006 Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98 1011-1014. (doi:10.1093/jnci/djj267)
7. Bakker GH, Setyono-Han B, Deckers GH & Klijn JGM 1990 Treatment of experimental breast cancer with new antiprogestins (ORG31710, ORG31806). European Journal of Cancer & Clinical Oncology 26 172.
8. Balleine RL, Earl MJ, Greenberg ML & Clarke CL 1999 Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. British Journal of Cancer 79 1564-1571. (doi:10.1038/sj.bjc.6690249)
9. Banks E, Beral V & Reeves G 1997 The epidemiology of epithelial ovarian cancer: a review. International Journal of Gynecological Cancer 7 425-438. (doi:10.1046/j.1525-1438.1997.09756.x)
10. Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Susumu N et al. 2012 Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review). International Journal of Oncology 40 1755-1762. (doi:10.3892/ijo.2012.1384)
11. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P & Brisken C 2010 Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. PNAS 107 2989-2994. (doi:10.1073/pnas.0915148107)
12. Beral V 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419-427. (doi:10.1016/S0140-6736(03)14596-5)
13. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT & Edwards DP 2001 Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Molecular Cell 8 269-280. (doi:10.1016/S1097-2765(01)00304-5)
14. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ & Edwards DP 2007 The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Molecular Endocrinology 21 359-375. (doi:10.1210/me.2006-0337)
15. Brisken C 2013 Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nature Reviews. Cancer 13 385-396. (doi:10.1038/nrc3518)
16. Brisken C & O’Malley B 2010 Hormone action in the mammary gland. Cold Spring Harbor Perspectives in Biology 2 a003178. (doi:10.1101/cshperspect.a003178)
17. Brisken C, Park S, Vass T, Lydon JP, O’Malley BW & Weinberg RA 1998 A paracrine role for the epithelial progesterone receptor in mammary gland development. PNAS 95 5076-5081. (doi:10.1073/pnas.95.9.5076)
18. Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR & Pei G 1997 Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79 1944-1950. (doi:10.1002/(SICI)1097-0142(19970515)79:10!1944::AID-CNCR15O3.0.CO;2-V)
19. Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma. Nature 474 609-615. (doi:10.1038/nature10166)
20. Chabbert-Buffet N, Meduri G, Bouchard P & Spitz IM 2005 Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update 11 293-307. (doi:10.1093/humupd/dmi002)
21. Charles D 1964 Iatrogenic endometrial patterns. Journal of Clinical Pathology 17 205-212. (doi:10.1136/jcp.17.3.205)
22. Chen B, Pan H, Zhu L, Deng Y & Pollard JW 2005 Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase/AKT/GSK-3b/cyclin D1/pRB pathway to block uterine epithelial cell proliferation. Molecular Endocrinology 19 1978-1990. (doi:10.1210/me.2004-0274)
23. Chlebowski RT & Anderson GL 2012 Changing concepts: menopausal hormone therapy and breast cancer. Journal of the National Cancer Institute 104 517-527. (doi:10.1093/jnci/djs014)
24. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE et al. 2009 Breast cancer after use of estrogen plus progestin in postmenopausal women. New England Journal of Medicine 360 573-587. (doi:10.1056/NEJMoa0807684)
25. Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R & Dubeau L 2005 Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Current Biology 15 561-565. (doi:10.1016/j.cub.2005.01.052)
26. Chung HH, Sze SK, Tay AS & Lin VC 2014 Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. Journal of Biological Chemistry 289 2180-2194. (doi:10.1074/jbc.M113.517896)
27. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W& Winkel CA 2007 A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility 87 1399-1412.
28. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C et al. 2004 Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Molecular and Cellular Biology 24 7260-7274. (doi:10.1128/MCB.24.16.7260-7274.2004)
29. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA & Richer JK 2013 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 32 2555-2564. (doi:10.1038/onc.2012.275)
30. Clancy KB 2009 Reproductive ecology and the endometrium: physiology, variation, and new directions. American Journal of Physical Anthropology 140 (Suppl 49) 137-154. (doi:10.1002/ajpa.21188)
31. Clevers H 2006 Wnt/b-catenin signaling in development and disease. Cell 127 469-480. (doi:10.1016/j.cell.2006.10.018)
32. Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347 1713-1727. (doi:10.1016/S0140-6736(96)90806-5)
33. Condon JC, Hardy DB, Kovaric K & Mendelson CR 2006 Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kB may contribute to the onset of labor through inhibition of PR function. Molecular Endocrinology 20 764-775. (doi:10.1210/me.2005-0242)
34. Conneely OM, Mulac-Jericevic B, Lydon JP & De Mayo FJ 2001 Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Molecular and Cellular Endocrinology 179 97-103. (doi:10.1016/S0303-7207(01)00465-8)
35. Conneely OM, Mulac-Jericevic B & Lydon JP 2003 Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68 771-778. (doi:10.1016/S0039-128X(03)00126-0)
36. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB & Cunha GR 1997 Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. PNAS 94 6535-6540. (doi:10.1073/pnas.94.12.6535)
37. Daniel AR & Lange CA 2009 Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. PNAS 106 14287-14292. (doi:10.1073/pnas.0905118106)
38. Daniel CW, Silberstein GB & Strickland P 1987 Direct action of 17b-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Research 47 6052-6057.
39. Daniel AR, Faivre EJ & Lange CA 2007 Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Molecular Endocrinology 21 2890-2906. (doi:10.1210/me.2007-0248)
40. Daniel AR, Knutson TP & Lange CA 2009 Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Molecular and Cellular Endocrinology 308 47-52. (doi:10.1016/j.mce.2009.01.004)
41. Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D & Lange CA 2010 The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Molecular Endocrinology 24 2126-2138. (doi:10.1210/me.2010-0170)
42. Daniel AR, Hagan CR & Lange CA 2011 Progesterone receptor action: defining a role in breast cancer. Expert Review of Endocrinology & Metabolism 6 359-369. (doi:10.1586/eem.11.25)
43. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D’Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D & Lange CA 2015 Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptorcontaining transcription complexes. Oncogene 34 506-515. (doi:10.1038/onc.2013.579)
44. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G & Chwalisz K 2003 Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68 1019-1032.
45. Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA & Lange CA 2013 Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 12 1433-1449. (doi:10.4161/cc.24550)
46. Dressing GE, Hagan CR, Knutson TP, Daniel AR & Lange CA 2009 Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocrine-Related Cancer 16 351-361. (doi:10.1677/ERC-08-0281)
47. Dressing GE, Knutson TP, Schiewer MJ, Daniel AR, Hagan CR, Diep CH, Knudsen KE & Lange CA 2014 Progesterone receptor-cyclin d1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Molecular Endocrinology 28 442-457. (doi:10.1210/me.2013-1196)
48. Edmondson RJ & Monaghan JM 2001 The epidemiology of ovarian cancer. International Journal of Gynecological Cancer 11 423-429. (doi:10.1046/j.1525-1438.2001.01053.x)
49. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA & Osborne CK 1993 Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Research and Treatment 26 237-246. (doi:10.1007/BF00665801)
50. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG & Gemzell- Danielsson K 2009 Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction 24 1870-1879.
51. Faivre EJ & Lange CA 2007 Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Srcdependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Molecular and Cellular Biology 27 466-480. (doi:10.1128/MCB.01539-06)
52. Faivre E, Skildum A, Pierson-Mullany L & Lange CA 2005 Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 70 418-426. (doi:10.1016/j.steroids.2005.02.012)
53. Faivre EJ, Daniel AR, Hillard CJ & Lange CA 2008 Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Molecular Endocrinology 22 823-837. (doi:10.1210/me.2007-0437)
54. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R & Nawata H 2007 Insulin-like growth factor 1/ insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. Journal of Biological Chemistry 282 7329-7338. (doi:10.1074/jbc.M610447200)
55. Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G & Darai E 2006 Effects of progesterone and anti-progestin (mifepristone) treatmentonproliferationand apoptosisof thehumanovariancancer cell line, OVCAR-3. Oncology Reports 15 743-748. (doi:10.3892/or.15.4.743)
56. Fleisch MC, Chou YC, Cardiff RD, Asaithambi A & Shyamala G 2009 Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia. Molecular Human Reproduction 15 241-249. (doi:10.1093/molehr/gap013)
57. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S & Crum CP 2008 A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology 109 168-173. (doi:10.1016/j.ygyno.2008.01.012)
58. Fournier A, Berrino F, Riboli E, Avenel V & Clavel-Chapelon F 2005 Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International Journal of Cancer 114 448-454. (doi:10.1002/ijc.20710)
59. Fournier A, Berrino F & Clavel-Chapelon F 2008 Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment 107 103-111. (doi:10.1007/s10549-007-9523-x)
60. Franco HL, Rubel CA, Large MJ, Wetendorf M, Fernandez-Valdivia R, Jeong JW, Spencer TE, Behringer RR, Lydon JP & Demayo FJ 2012 Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. FASEB Journal 26 1218-1227. (doi:10.1096/fj.11-193334)
61. Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RC, Steel CM, Porteous DJ & Smyth JF 1996 Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Research 56 950-954.
62. Giangrande PH, Kimbrel EA, Edwards DP & McDonnell DP 2000 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Molecular and Cellular Biology 20 3102-3115. (doi:10.1128/MCB.20.9.3102-3115.2000)
63. Giulianelli S, Vaque JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA et al. 2012 Estrogen receptor a mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Research 72 2416-2427. (doi:10.1158/0008-5472.CAN-11-3290)
64. Goto T, Takano M, Hirata J & Tsuda H 2008 The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. British Journal of Cancer 98 1068-1075. (doi:10.1038/sj.bjc.6604279)
65. Goyeneche AA & Telleria CM 2015 Antiprogestins in gynecological diseases. Reproduction 149 R15-R33. (doi:10.1530/REP-14-0416)
66. Graham JD & Clarke CL 1997 Physiological action of progesterone in target tissues. Endocrine Reviews 18 502-519. (doi:10.1210/edrv.18.4.0308)
67. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR & Clarke CL 2009 DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150 3318-3326. (doi:10.1210/en.2008-1630)
68. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA & Horwitz KB 1997 Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Molecular Endocrinology 11 1593-1607. (doi:10.1210/mend.11.11.0006)
69. Gross GE, Clark GM, Chamness GC & McGuire WL 1984 Multiple progesterone receptor assays in human breast cancer. Cancer Research 44 836-840.
70. Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R & Mehta RG 2013 Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 133 30-42.
71. Hagan CR & Lange CA 2014 Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Medicine 12 32. (doi:10.1186/1741-7015-12-32)
72. Hagan CR, Regan TM, Dressing GE & Lange CA 2011a ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Molecular and Cellular Biology 31 2439-2452. (doi:10.1128/MCB.01246-10)
73. Hagan CR, Daniel AR, Dressing GE & Lange CA 2011b Role of phosphorylation in progesterone receptor signaling and specificity. Molecular and Cellular Endocrinology 357 43-49. (doi:10.1016/j.mce.2011.09.017)
74. Hagan CR, Knutson TP & Lange CA 2013 A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Research 41 8926-8942. (doi:10.1093/nar/gkt706)
75. Han SJ, Jeong J, Demayo FJ, Xu J, Tsai SY, Tsai MJ & O’Malley BW 2005 Dynamic cell type specificity of SRC-1 coactivator in modulating uterine progesterone receptor function in mice. Molecular and Cellular Biology 25 8150-8165. (doi:10.1128/MCB.25.18.8150-8165.2005)
76. Han SJ, Tsai SY, Tsai MJ & O’Malley BW 2007 Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. Endocrinology 148 2471-2486. (doi:10.1210/en.2006-1561)
77. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B & Stampfer MJ 1992 A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstetrics and Gynecology 80 708-714.
78. Hecht JL & Mutter GL 2006 Molecular and pathologic aspects of endometrial carcinogenesis. Journal of Clinical Oncology 24 4783-4791. (doi:10.1200/JCO.2006.06.7173)
79. Hedrick SM, Hess Michelini R, Doedens AL, Goldrath AW & Stone EL 2012 FOXO transcription factors throughout T cell biology. Nature Reviews. Immunology 12 649-661. (doi:10.1038/nri3278)
80. Helle SI, Jonat W, Giurescu M, Ekse D, Holly JM & Lonning PE 1998 Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 66 159-163.
81. Hempling RE, Piver MS, Eltabbakh GH & Recio FO 1998 Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. American Journal of Clinical Oncology 21 447-451. (doi:10.1097/00000421-199810000-00005)
82. Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, Mote PA & Clarke CL 2012 Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Molecular and Cellular Endocrinology 361 191-201. (doi:10.1016/j.mce.2012.04.010)
83. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ & Kjaer SK 2007 Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ’MALOVA’ ovarian cancer study. Oncology Reports 18 1051-1059. (doi:10.3892/or.18.5.1051)
84. Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R & Dubeau L 2010 Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Research 70 221-228. (doi:10.1158/0008-5472.CAN-09-3232)
85. Horwitz KB & Sartorius CA 2008 Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. Journal of Clinical Endocrinology and Metabolism 93 3295-3298. (doi:10.1210/jc.2008-0938)
86. Horwitz KB, Dye WW, Harrell JC, Kabos P & Sartorius CA 2008 Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. PNAS 105 5774-5779. (doi:10.1073/pnas.0706216105)
87. Hou X, Tan Y, Li M, Dey SK & Das SK 2004 Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Molecular Endocrinology 18 3035-3049. (doi:10.1210/me.2004-0259)
88. Hovland AR, Powell RL, Takimoto GS, Tung L & Horwitz KB 1998 An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. Journal of Biological Chemistry 273 5455-5460. (doi:10.1074/jbc.273.10.5455)
89. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ & Willett WC 2010 Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiology, Biomarkers & Prevention 19 2496-2502. (doi:10.1158/1055-9965.EPI-10-0747)
90. Ioffe OB, Zaino RJ & Mutter GL 2009 Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Modern Pathology 22 450-459.
91. Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, Iruela-Arispe ML & Memarzadeh S 2013 Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Research 73 4697-4710. (doi:10.1158/0008-5472.CAN-13-0930)
92. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
93. Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U & Robertson JF 2013 Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Annals of Oncology 24 2543-2548.
94. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 55 3331-3338.
95. Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW & Brosens JJ 2006 Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. PNAS 103 16272-16277. (doi:10.1073/pnas.0603002103)
96. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H & Hollema H 2009 Expression of estrogen receptor-a and -b and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecologic Oncology 112 537-542. (doi:10.1016/j.ygyno.2008.10.032)
97. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD & Khokha R 2010 Progesterone induces adult mammary stem cell expansion. Nature 465 803-807. (doi:10.1038/nature09091)
98. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S et al. 2001 Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Letters 167 39-48. (doi:10.1016/S0304-3835(01)00462-1)
99. Kariagina A, Aupperlee MD & Haslam SZ 2008 Progesterone receptor isoform functions in normal breast development and breast cancer. Critical Reviews in Eukaryotic Gene Expression 18 11-33. (doi:10.1615/CritRevEukarGeneExpr.v18.i1.20)
100. Karst AM, Levanon K & Drapkin R 2011 Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS 108 7547-7552. (doi:10.1073/pnas.1017300108)
101. Keith Bechtel M & Bonavida B 2001 Inhibitory effects of 17b-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecologic Oncology 82 127-138. (doi:10.1006/gyno.2001.6221)
102. Khan JA, Tikad A, Fay M, Hamze A, Fagart J, Chabbert-Buffet N, Meduri G, Amazit L, Brion JD, Alami M et al. 2013 A new strategy for selective targeting of progesterone receptor with passive antagonists. Molecular Endocrinology 27 909-924.
103. Khunamornpong S, Suprasert P, Chiangmai WN & Siriaunkgul S 2006 Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. International Journal of Gynecological Cancer 16 (Suppl 1) 132-138. (doi:10.1111/j.1525-1438.2006.00302.x)
104. Kim JJ & Chapman-Davis E 2010 Role of progesterone in endometrial cancer. Seminars in Reproductive Medicine 28 81-90. (doi:10.1055/s-0029-1242998)
105. Kim JJ, Buzzio OL, Li S & Lu Z 2005 Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biology of Reproduction 73 833-839. (doi:10.1095/biolreprod.105.043182)
106. Kim JJ, Kurita T & Bulun SE 2013 Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine Reviews 34 130-162. (doi:10.1210/er.2012-1043)
107. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ & Alexieva- Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49 2851-2856.
108. Knutson TP & Lange CA 2014 Tracking progesterone receptor-mediated actions in breast cancer. Pharmacology & Therapeutics 142 114-125. (doi:10.1016/j.pharmthera.2013.11.010)
109. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA & Lange CA 2012a Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Research 14 R95. (doi:10.1186/bcr3211)
110. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA & Lange CA 2012b Phosphorylated and small ubiquitin-like modifier protein-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Research 14 R95. (doi:10.1186/bcr3211)
111. Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I & Shalev E 2014 Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagnostic Pathology 9 77. (doi:10.1186/1746-1596-9-77)
112. Kurita T, Young P, Brody JR, Lydon JP, O’Malley BW & Cunha GR 1998 Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 139 4708-4713. (doi:10.1210/en.139.11.4708)
113. Kyo S, Sakaguchi J, Kiyono T, Shimizu Y, Maida Y, Mizumoto Y, Mori N, Nakamura M, Takakura M, Miyake K et al. 2011 Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth. Clinical Cancer Research 17 525-537. (doi:10.1158/1078-0432.CCR-10-1287)
114. Lange CA, Shen T & Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. PNAS 97 1032-1037. (doi:10.1073/pnas.97.3.1032)
115. Lee P, Rosen DG, Zhu C, Silva EG & Liu J 2005 Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecologic Oncology 96 671-677. (doi:10.1016/j.ygyno.2004.11.010)
116. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW et al. 2007 A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Journal of Pathology 211 26-35. (doi:10.1002/path.2091)
117. Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K & Jeschke U 2012 Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 12 553. (doi:10.1186/1471-2407-12-553)
118. Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB & Lange C 1997 Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Annals of the New York Academy of Sciences 828 17-26. (doi:10.1111/j.1749-6632.1997.tb48520.x)
119. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W & Nieman LK 2008 CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology 111 1129-1136.
120. Li P, Lee H, Guo S, Unterman TG, Jenster G & Bai W 2003 AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Molecular and Cellular Biology 23 104-118. (doi:10.1128/MCB.23.1.104-118.2003)
121. Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, Bagchi MK & Bagchi IC 2011 The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 331 912-916. (doi:10.1126/science.1197454)
122. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR & Malone KE 2012 Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Research 72 2028-2035. (doi:10.1158/0008-5472.CAN-11-4064)
123. Lindgren P, Backstrom T, Mahlck CG, Ridderheim M & Cajander S 2001 Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. International Journal of Oncology 19 31-38. (doi:10.3892/ijo.19.1.31)
124. Lo AT, Mori H, Mott J & Bissell MJ 2012 Constructing three-dimensional models to study mammary gland branching morphogenesis and functional differentiation. Journal of Mammary Gland Biology and Neoplasia 17 103-110. (doi:10.1007/s10911-012-9251-7)
125. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM & O’Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes and Development 9 2266-2278. (doi:10.1101/gad.9.18.2266)
126. Lyytinen HK, Dyba T, Ylikorkala O & Pukkala EI 2010 A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. International Journal of Cancer 126 483-489. (doi:10.1002/ijc.24738)
127. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Benes V, Roche H, Dalenc F, Auboeuf D, Millevoi S et al. 2009 Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Research 69 8332-8340. (doi:10.1158/0008-5472.CAN-09-2206)
128. McCampbell AS, Broaddus RR, Loose DS & Davies PJ 2006 Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clinical Cancer Research 12 6373-6378. (doi:10.1158/1078-0432.CCR-06-0912)
129. Mendelson CR 2009 Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Molecular Endocrinology 23 947-954. (doi:10.1210/me.2009-0016)
130. Merlino AA, Welsh TN, Tan H, Yi LJ, Cannon V, Mercer BM & Mesiano S 2007 Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A. Journal of Clinical Endocrinology and Metabolism 92 1927-1933. (doi:10.1210/jc.2007-0077)
131. Mesiano S, Chan EC, Fitter JT, Kwek K, Yeo G & Smith R 2002 Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. Journal of Clinical Endocrinology and Metabolism 87 2924-2930. (doi:10.1210/jcem.87.6.8609)
132. Mesiano S, Wang Y & Norwitz ER 2011 Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reproductive Sciences 18 6-19. (doi:10.1177/1933719110382922)
133. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M & Auricchio F 1998 Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO Journal 17 2008-2018. (doi:10.1093/emboj/17.7.2008)
134. Miyamoto T, Watanabe J, Hata H, Jobo T, Kawaguchi M, Hattori M, Saito M & Kuramoto H 2004 Significance of progesterone receptor-A and -B expressions inendometrial adenocarcinoma. Journal of Steroid Biochemistry and Molecular Biology 92 111-118. (doi:10.1016/j.jsbmb.2004.07.007)
135. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P & Oesterreich S 2012 Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocrine-Related Cancer 19 R255-R279. (doi:10.1530/ERC-12-0175)
136. Mote PA, Balleine RL, McGowan EM & Clarke CL 1999 Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 84 2963-2971. (doi:10.1210/jcem.84.8.5928)
137. Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL & kConFab Investigators 2004 Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes, Chromosomes & Cancer 39 236-248. (doi:10.1002/gcc.10321)
138. Mote PA, Graham JD & Clarke CL 2007 Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Foundation Symposium Proceedings 1 77-107. (doi:10.1007/2789_2008_076)
139. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP & Conneely OM 2000 Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289 1751-1754. (doi:10.1126/science.289.5485.1751)
140. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R & Franke FE 2000 Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 1783-1791. (doi:10.1002/1097-0142(20001015)89:8!1783::AID-CNCR19O3.0.CO;2-D)
141. Musgrove EA, Lee CS & Sutherland RL 1991 Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Molecular and Cellular Biology 11 5032-5043. (doi:10.1128.MCB.11.10.5032)
142. Myatt SS & Lam EW 2007 The emerging roles of forkhead box (Fox) proteins in cancer. Nature Reviews. Cancer 7 847-859. (doi:10.1038/nrc2223)
143. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kunze S, Dian D, Friedl C, Kupka MS & Friese K 2007 Steroid receptors ERa, ERb, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histology and Histopathology 22 169-176.
144. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD & Buchanan G 2012 Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor a in luminal breast cancer cells. Molecular Endocrinology 26 1941-1952. (doi:10.1210/me.2011-1314)
145. Nickisch K, Nair HB, Kesavaram N, Das B, Garfield R, Shi SQ, Bhaskaran SS, Grimm SL & Edwards DP 2013 Synthesis and antiprogestational properties of novel 17-fluorinated steroids. Steroids 78 909-919.
146. Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA & Swisher EM 2010 The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116 5261-5271. (doi:10.1002/cncr.25439)
147. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ & Campbell IG 1998 Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Research 58 2095-2097.
148. Owen GI, Richer JK, Tung L, Takimoto G & Horwitz KB 1998 Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. Journal of Biological Chemistry 273 10696-10701. (doi:10.1074/jbc.273.17.10696)
149. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP & Oesterreich S 2011 Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical Cancer Research 17 4177-4186. (doi:10.1158/1078-0432.CCR-10-2950)
150. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T & Fisher B 1996 Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Journal of Clinical Oncology 14 2709-2712.
151. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al. 2009 Androgen receptor inhibits estrogen receptor-a activity and is prognostic in breast cancer. Cancer Research 69 6131-6140. (doi:10.1158/0008-5472.CAN-09-0452)
152. Pieber D, Allport VC, Hills F, Johnson M & Bennett PR 2001 Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction 7 875-879. (doi:10.1093/molehr/7.9.875)
153. Pierson-Mullany LK & Lange CA 2004 Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activatoin of cyclin-dependent protein kinase2. Molecular and Cellular Biology 24 10542-10547. (doi:10.1128/MCB.24.24.10542-10557.2004)
154. Qiu M & Lange CA 2003 MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. Journal of Steroid Biochemistry and Molecular Biology 85 147-157. (doi:10.1016/S0960-0760(03)00221-8)
155. Ramsey EM, Houston ML & Harris JW 1976 Interactions of the trophoblast and maternal tissues in three closely related primate species. American Journal of Obstetrics and Gynecology 124 647-652.
156. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB & Burke T 2009 Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115 1867-1874.
157. Ren Y, Liu X, Ma D, Feng Y & Zhong N 2007 Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genetics and Cytogenetics 175 107-116. (doi:10.1016/j.cancergencyto.2007.02.002)
158. Richer JK, Lange CA, Manning NG, Owen G, Powell R & Horwitz KB 1998 Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. Journal of Biological Chemistry 273 31317-31326. (doi:10.1074/jbc.273.47.31317)
159. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM & Horwitz KB 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. Journal of Biological Chemistry 277 5209-5218. (doi:10.1074/jbc.M110090200)
160. Robertson JF, Willsher PC, Winterbottom L, Blamey RW & Thorpe S 1999 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. European Journal of Cancer 35 214-218.
161. Rocereto TF, Saul HM, Aikins JA Jr & Paulson J 2000 Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecologic Oncology 77 429-432.
162. Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J & Mannel RS 2010 A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecologic Oncology 116 332-334. (doi:10.1016/j.ygyno.2009.10.071)
163. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S & Rochefort H 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bulletin du Cancer 74 455-461.
164. Rudd MD, Gonzalez-Robayna I, Hernandez-Gonzalez I, Weigel NL, Bingman WE III & Richards JS 2007 Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. Journal of Molecular Endocrinology 38 673-690. (doi:10.1677/JME-07-0017)
165. Sakaguchi H, Fujimoto J, Hong BL, Nakagawa Y & Tamaya T 2004 Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecologic Oncology 93 394-399. (doi:10.1016/j.ygyno.2004.01.042)
166. Salghetti SE, Caudy AA, Chenoweth JG & Tansey WP 2001 Regulation of transcriptional activation domain function by ubiquitin. Science 293 1651-1653. (doi:10.1126/science.1062079)
167. Samarnthai N, Hall K & Yeh IT 2010 Molecular profiling of endometrial malignancies. Obstetrics and Gynecology International 2010 162363. (doi:10.1155/2010/162363)
168. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S & Dahiya R 2001 Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Research 61 97-102.
169. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T & Noguchi M 2000 Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Research 60 7052-7056.
170. Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA & Weigel RJ 2001 Ligand-dependent interaction of estrogen receptor-a with members of the forkhead transcription factor family. Journal of Biological Chemistry 276 33554-33560. (doi:10.1074/jbc.M105555200)
171. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H et al. 2007 Prognostic significance of oestrogen receptor a (ERa) and b (ERb), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. European Journal of Cancer 43 2434-2444. (doi:10.1016/j.ejca.2007.08.014)
172. Shao R 2013 Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. Ecancermedicalscience 7 381. (doi:10.3332/ecancer.2013.381)
173. Sieh W, Kobel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB et al. 2013 Hormonereceptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet. Oncology 14 853-862. (doi:10.1016/S1470-2045(13)70253-5)
174. Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, Dietel M & Denkert C 2011 Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology 59 918-927. (doi:10.1111/j.1365-2559.2011.04028.x)
175. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J & Pukkala E 2014 Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstetrics and Gynecology 124 292-299. (doi:10.1097/AOG.0000000000000356)
176. Song LN, Coghlan M & Gelmann EP 2004 Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Molecular Endocrinology 18 70-85. (doi:10.1210/me.2003-0189)
177. Spitz IM 2006 Progesterone receptor antagonists. Current Opinion in Investigational Drugs 7 882-890.
178. Spitz IM & Bardin CW 1993 Mifepristone (RU 486)- a modulator of progestin and glucocorticoid action. New England Journal of Medicine 329 404-412. (doi:10.1056/NEJM199308053290607)
179. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E & Groner B 1999 Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. Journal of Steroid Biochemistry and Molecular Biology 69 195-204. (doi:10.1016/S0960-0760(99)00052-7)
180. Syed V & Ho SM 2003 Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22 6883-6890. (doi:10.1038/sj.onc.1206828)
181. Syed V, Ulinski G, Mok SC, Yiu GK & Ho SM 2001 Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Research 61 6768-6776.
182. Takamoto N, Zhao B, Tsai SY & DeMayo FJ 2002 Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. Molecular Endocrinology 16 2338-2348. (doi:10.1210/me.2001-0154)
183. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA et al. 2006 Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 147 1097-1121. (doi:10.1210/en.2005-1076)
184. Tang HY, Lin HY, Zhang S, Davis FB & Davis PJ 2004 Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145 3265-3272. (doi:10.1210/en.2004-0308)
185. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S & Tanwanich S 2009 Expressions of estrogen and progesterone receptors in epithelialovariancancer: a clinicopathologic study. International Journal of Gynecological Cancer 19 620-627. (doi:10.1111/IGC.0b013e3181a44b62)
186. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P et al. 2013 Progesterone/ RANKL is a major regulatory axis in the human breast. Science Translational Medicine 5 182ra155. (doi:10.1126/scitranslmed.3005654)
187. Tong W & Pollard JW 1999 Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Molecular and Cellular Biology 19 2251-2264.
188. Tora L, Gronemeyer H, Turcotte B, Gaub MP & Chambon P 1988 The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 333 185-188. (doi:10.1038/333185a0)
189. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T et al. 2007 Multicenter phase II study offertilitysparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. Journal of Clinical Oncology 25 2798-2803. (doi:10.1200/JCO.2006.08.8344)
190. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW & McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Molecular Endocrinology 7 1244-1255. (doi:10.1210/mend.7.10.8264658)
191. Venkitaraman AR 2002 Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 171-182. (doi:10.1016/S0092-8674(02)00615-3)
192. Wang S, Counterman LJ & Haslam SZ 1990 Progesterone action in normal mouse mammary gland. Endocrinology 127 2183-2189. (doi:10.1210/endo-127-5-2183)
193. Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA et al. 2009 Progesterone inhibition of Wnt/b-catenin signaling in normal endometrium and endometrial cancer. Clinical Cancer Research 15 5784-5793. (doi:10.1158/1078-0432.CCR-09-0814)
194. Wang Y, van der Zee M, Fodde R & Blok LJ 2010 Wnt/b-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget 1 674-684.
195. Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC & Kim JJ 2008 The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149 1942-1950. (doi:10.1210/en.2007-0756)
196. Wetendorf M & DeMayo FJ 2012 The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. Molecular and Cellular Endocrinology 357 108-118. (doi:10.1016/j.mce.2011.10.028)
197. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA et al. 2013 The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet. Oncology 14 1226-1232. (doi:10.1016/S1470-2045(13)70448-0)
198. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA et al. 2013 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Reports 5 637-645. (doi:10.1016/j.celrep.2013.10.006)
199. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC & Jiang SW 2005 Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecologic Oncology 99 135-141. (doi:10.1016/j.ygyno.2005.05.035)
200. Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW & Hennighausen L 2009 Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes and Development 23 2382-2387. (doi:10.1101/gad.1840109)
201. Yang XY, Xi MR, Yang KX & Yu H 2009 Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecologic Oncology 113 99-104. (doi:10.1016/j.ygyno.2008.12.018)
202. Yang S, Thiel KW & Leslie KK 2011 Progesterone: the ultimate endometrial tumor suppressor. Trends in Endocrinology and Metabolism 22 145-152. (doi:10.1016/j.tem.2011.01.005)
203. Yang S, Xiao X, Jia Y, Liu X, Zhang Y, Wang X, Winters CJ, Devor EJ, Meng X, Thiel KW et al. 2014 Epigenetic modification restores functional PR expression in endometrial cancer cells. Current Pharmaceutical Design 20 1874-1880. (doi:10.2174/13816128113199990532)
204. Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB & Mor G 2014 Ovulation and extra-ovarian origin of ovarian cancer. Scientific Reports 4 6116. (doi:10.1038/srep06116)
205. Yen HY, Gabet Y, Liu Y, Martin A, Wu NL, Pike MC, Frenkel B, Maxson R & Dubeau L 2012 Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Laboratory Investigation 92 802-811. (doi:10.1038/labinvest.2012.58)
206. Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D& Seidman DS 2014 Vaginalmifepristone for the treatment of symptomatic uterine leiomyomata: anopen-label study. Fertility and Sterility 101496-500.
207. Yu S, Lee M, Shin S & Park J 2001 Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. Journal of Cellular Biochemistry 82 445-451. (doi:10.1002/jcb.1171)
208. Yudt MR, Russo LA, Berrodin TJ, Jelinsky SA, Ellis D, Cohen JC, Cooch N, Haglund E, Unwalla RJ, Fensome A et al. 2011 Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions. Biochemical Pharmacology 82 1709-1719.
209. Yudt MR, Berrodin TJ, Jelinsky SA, Hanna LA, Brown EL, Chippari S, Bhat RA, Winneker RC & Zhang Z 2006 Selective and opposing actions of progesterone receptor isoforms in human endometrial stromal cells. Molecular and Cellular Endocrinology 247 116-126. (doi:10.1016/j.mce.2005.12.012)
210. Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, Pan X, Li AL, Gong WL, Jin BF et al. 2007 CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO Journal 26 1831-1842. (doi:10.1038/sj.emboj.7601602)